SEC Company Response from Aptose Biosciences Inc. (CIK 0000882361) (APTOF) — Feb 26, 2010

Aptose Biosciences Inc. (CIK 0000882361)
Date: Feb. 26, 2010 · CIK: 0000882361 · Accession: 0001279569-10-000216

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 001-32001

Date

February 26, 2010

Author

/s/ Mark Preston

Form

CORRESP

Company

Aptose Biosciences Inc. (CIK 0000882361)

Letter

Securities and Exchange Commission 100 F Street, NE Washington, D.C. Filed: EDGAR/CORRESP

Re: Comment Letter, dated February 18, 2010 related to Form 20-F for fiscal year ended May 31, 2009 (the “Comment Letter”) File No. 001-32001

Dear Sirs and Mesdames,

Lorus Therapeutics Inc. hereby notifies the Securities and Exchange Commission that it currently expects to provide responses to the comments contained in the Comment Letter on or before March 19, 2010.

Sincerely,
/s/ Mark Preston

Show Raw Text

CORRESP
1
filename1.htm

    corresp.htm

February 26, 2010

Securities and Exchange Commission

100 F Street, NE

Washington, D.C.

20549

Filed: EDGAR/CORRESP

Dear Sirs and Mesdames,

Re:              Comment Letter, dated February 18, 2010 related to Form
20-F for fiscal year ended May 31, 2009 (the “Comment Letter”) File No. 001-32001

Lorus Therapeutics Inc. hereby notifies the Securities and Exchange Commission that it currently expects to provide responses to the comments contained in the Comment Letter on or before March 19, 2010.

Sincerely,

/s/ Mark Preston

Mark Preston,

Acting Controller

SecProbe.io